5414002026-04-012026-06-305414002026-04-012026-06-30in-capmkt:OtherExpenses1Member5414002026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2026-04-012027-03-312026-08-062026-07-31INRLakhsQuarterlyFirst quarterSingle segmentPharmacuetical Industry2026-08-0610:30:002026-08-0613:50:00Not applicable2026-04-012026-06-30UnauditedConsolidated94178500099230009517080004381610005091000-4858700019183700036434000537220003307800001007438000-557300000-557300002000-15562000-155600000-401700000000-401700003695000-36475000-40168000-2000-36473000-200053549000010-0.75-0.7500-0.75-0.750.0050.0053-0.0053Notes : <br /> <br /> 1) The above statement of consolidated financial results of ZIM Laboratories Limited ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'Group') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 August 2026 and 06 August 2026. The above results have been subjected to limited review by Statutory Auditor of the Company. <br /> <br /> 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI). <br /> <br /> 3) The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the year ended 31 March 2026 and year to date figures upto 31 December 2025, on which auditors had performed a limited review. <br /> <br /> 4) The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments. <br /> <br /> <br /> <br /> <br /> <br /> Other Expenses330780000Measurement of defined employee benefit plans-346000-346000-101000Exchange difference on translation of foreign operations3940000394000003695000